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Background: Transforming growth factor (TGF)-β plays a pivotal role in cancer progression through regulating
cancer cell proliferation, invasion, and remodeling of the tumor microenvironment. Cancer-associated fibroblasts
(CAFs) are the predominant type of stromal cell, in which TGF-β signaling is activated. Among the strategies for
TGF-β signaling inhibition, RNA interference (RNAi) targeting of TGF-β ligands is emerging as a promising tool.
Although preclinical studies support the efficacy of this therapeutic strategy, its effect on the tumor microenvironment
in vivo remains unknown. In addition, differential effects due to knockdown of various TGF-β ligand isoforms have
not been examined. Therefore, an experimental model that recapitulates tumor–stromal interaction is required for
validation of therapeutic agents.
Methods: We have previously established a three-dimensional co-culture model of lung cancer, and demonstrated
the functional role of co-cultured fibroblasts in enhancing cancer cell invasion and differentiation. Here, we employed
this model to examine how knockdown of TGF-β ligands affects the behavior of different cell types. We developed
lentivirus vectors carrying artificial microRNAs against human TGF-β1 and TGF-β2, and tested their effects in lung
cancer cells and fibroblasts.
Results: Lentiviral vectors potently and selectively suppressed the expression of TGF-β ligands, and showed
anti-proliferative effects on these cells. Furthermore, knockdown of TGF-β ligands attenuated fibroblast-mediated
collagen gel contraction, and diminished lung cancer cell invasion in three-dimensional co-culture. We also
observed differential effects by targeting different TGF-β isoforms in lung cancer cells and fibroblasts.
Conclusions: Our findings support the notion that RNAi-mediated targeting of TGF-β ligands may be beneficial
for lung cancer treatment via its action on both cancer and stromal cells. This study further demonstrates the
usefulness of this three-dimensional co-culture model to examine the effect of therapeutic agents on tumor–stromal
interaction.
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Lung cancer causes the deaths of more than one million
people worldwide every year [1]. Despite recent progress
in molecular-targeted therapeutics, such as inhibitors of
epidermal growth factor receptor (EGFR) tyrosine kinase
and anaplastic lymphoma kinase (ALK), failure to achieve
long-lasting therapeutic responses has emphasized the
need for novel treatment strategies [2,3].
Most forms of cancer are associated with a stromal
response and extracellular matrix (ECM) deposition,
referred to as desmoplasia, which is critically regulated
by cancer-associated fibroblasts (CAFs) [4]. Cancer tissue
remodeling allows tumor cells to grow and disseminate,
and contributes to increased interstitial fluid pressure,
which can be an obstacle to drug delivery [5].
Among the soluble factors involved in the tumor–stro-
mal interaction, transforming growth factor (TGF)-β plays
a pivotal role. In premalignant stages, TGF-β acts as a
tumor suppressor by inhibiting proliferation and apoptotic
induction in epithelial cells. In later stages, epithelial cells
become refractory to the growth inhibitory effect of TGF-
β and begin to secrete high levels of TGF-β, which in turn
exhibits tumor-promoting activity, such as angiogenesis,
immune evasion, fibroblast activation, and ECM accumu-
lation [6-8]. Furthermore, TGF-β increases the migratory
and invasive capacity of cancer cells by inducing the
epithelial–mesenchymal transition (EMT) [9,10]. Indeed,
TGF-β levels in both serum and tissues were elevated and
associated with worsening prognosis in patients with lung
cancer [11,12]. As such, TGF-β may be a promising target
for cancer therapy. However, in contrast to cancer cells,
the role of TGF-β signaling in the tumor stroma is poorly
understood, at least partly due to technical limitations in
detecting TGF-β signaling activation in situ.
RNA interference (RNAi) has been used widely to in-
duce the potent and specific inhibition of gene expres-
sion. Several variants of small regulatory RNAs are
involved in RNAi, including synthetic double-stranded
small interfering RNAs (siRNAs), RNA polymerase III
(pol III)-transcribed small hairpin RNAs (shRNAs), and
endogenous or artificial microRNAs (miRNAs) that are
transcribed by RNA polymerase II (pol II) as pri-miRNA,
and subsequently processed into mature miRNAs [13,14].
Vectors that enable the expression of engineered miRNA
sequences from Pol II promoters have been developed
[15], in which the stem sequences of an endogenous
miRNA precursor are substituted with unrelated base-
paired sequences that target specific genes.
Among the therapeutic strategies for TGF-β signaling
inhibition, RNAi is emerging as a promising tool [13].
Recent advances in RNAi technology are overcoming
previous obstacles, such as instability in vivo, impeded
drug delivery, and undesirable off-target effects. In ani-
mal experiments, RNAi agents directed against TGF-βligands have successfully ameliorated outcomes in dis-
ease models [16], and raised hope that this approach
may be useful in a clinical setting.
However, the three isoforms of TGF-β ligands—TGF-
β1, TGF-β2, and TGF-β3—show different expression pro-
files in various tissues and cell types. To develop effective
therapeutic strategies for silencing TGF-β ligands, iden-
tifying the appropriate isoform and target cell type may
be critical. To our knowledge, the differential effects of
eliminating specific TGF-β isoforms in a given tissue
type remain unstudied.
In the present study, we explored the therapeutic
effect of TGF-β signaling blockade in lung cancer.
We previously developed a three-dimensional (3D)
co-culture model for evaluation of tumor–stromal inter-
actions [17]. Using this model, we tested the differential
effects of silencing TGF-β ligands in A549 lung cancer
cells and HFL-1 lung fibroblasts. Among the three iso-
forms of TGF-β ligands, TGF-β1 and TGF-β2 (but not
TGF-β3) are dominantly expressed in these cells [18-20].
Thus we established lentiviral vectors that transduce artifi-
cial miRNAs against human TGF-β1 and TGF-β2 as a tool
for testing the effects of TGF-β ligand knockdown.
Methods
Cell culture
Tissue culture media and supplements were purchased
from GIBCO (Life Technologies, Grand Island, NY).
A549 human lung adenocarcinoma cells and HFL-1
human lung fibroblasts were purchased from the American
Type Culture Collection (Rockville, MD), and were cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS). In
addition, 293FT cells were obtained from Invitrogen
(Carlsbad, CA), and cultured in 100-mm dish coated
with collagen type I (IWAKI, Tokyo, Japan) in DMEM
with 10% FBS and 1 mM sodium pyruvate.
Artificial miRNA sequences
The BLOCK-iT™ Pol II miR RNAi Expression Vector Kit
with EmGFP (Invitrogen, Carlsbad, CA) was used for
RNAi experiments. The design of the expression vector
was based on the use of endogenous murine miR-155
flanking sequences. Artificial miRNA sequences target-
ing human TGF-β ligands were designed using BLOCK-
iT™ RNAi Designer (http://rnaidesigner.Invitrogen.com/
rnaiexpress/). Four and three pairs of sense and anti-
sense oligonucleotides were designed for targeting hu-
man TGF-β1 and β2, respectively (Additional file 1:
Table S1).
Plasmid construction and preparation of viral vectors
The designed oligonucleotides were annealed, followed
by ligation into the pcDNA6.2-GW/EmGFP-miR vector
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tination vector via Gateway recombination reactions.
The EmGFP forward sequence primer (5′- GGCATG-
GACGAGCTGTACAA −3′) was used for sequencing of
the miRNA insert fragments, which was performed
using an ABI PRISM® 310 Genetic Analyzer. As the con-
trol, pcDNA6.2-GW/EmGFP-miR negative control plas-
mid (Invitrogen) was used. The sequence containing the
miRNA coding region was transferred to the lentivirus
vector via the Gateway cloning system (Invitrogen).
Briefly, the miRNA coding region was subcloned into
the entry plasmid pDONR221 (Invitrogen) using Gateway®
BP Clonase™ II Enzyme Mix (Invitrogen). The sequences
in the entry plasmids were then transferred to the lenti-
viral expression vector, pCSII-EF-RfA, using Gateway® LR
Clonase™ II Enzyme Mix (Invitrogen).
Lentivirus infection
The recombinant lentivirus was produced by transfec-
tion of 293FT cells with the lentiviral expression vec-
tors, pCMV-VSV-G-RSV-Rev, and pCAG-HIVgp, using
Lipofectamine 2000 reagent (Invitrogen). After 72 h, the
medium was collected, and 1 × 105 of A549 or HFL-1
cells were infected with 500 μL of medium containing
lentiviruses. For double knockdown of TGF-β1 and
TGF-β2, 250 μL of each lentivirus-containing medium
were used. Infection efficiency was assessed by measur-
ing the percentage of EmGFP-positive cells via flow cy-
tometry (EPICS XL System II; Beckman Coulter, Brea,
CA), and knockdown efficiency of target gene was ana-
lyzed using an enzyme-linked immunosorbent assay
(ELISA).
RT-PCR
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Tokyo, Japan). The cDNA was synthesized
using SuperScript III Reverse Transcriptase (Invitrogen),
following the manufacturer’s protocol. Quantitative
reverse transcription (RT)-PCR was performed using
Mx-3000P (Stratagene, La Jolla, CA) and QuantiTect
SYBR Green PCR (Qiagen). Relative mRNA expression
was calculated using the ΔΔCt method, and expression
was normalized to that of the glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) gene. The specific primers are
shown in Additional file 2: Table S2.
ELISA for TGF-β1 and TGF-β2
A549 and HFL-1 cells were serum-starved for 24 h, and
each supernatant was collected. The concentrations of
TGF-β1 and TGF-β2 were measured using the Quanti-
kine ELISA for human TGF-β1/TGF-β2 (R&D Systems,
Minneapolis, MN), according to the manufacturer’s in-
structions. Each supernatant was activated by 1 N HCl,
followed by neutralization with 1.2 N NaOH/0.5 M HEPES.The optical density of each reaction was measured at
450 nm using a microplate reader (Bio-Rad, Hercules, CA),
and corrected against absorption at 570 nm. The
data were analyzed using the Microplate Manager III
Macintosh data analysis software (Bio-Rad).
Cell proliferation assay
A549 cells were seeded at a density of 1 × 104/well on
12-well dishes and HFL-1 cells were seeded at 4 × 104/
well on 6-well dishes. Both cell types were cultured in
DMEM containing 10% FBS. Cells were counted on days
1, 3, and 5 after seeding using a hemocytometer.
Collagen gel contraction assay and 3D co-culture
Three-dimensional gel cultures were carried out accord-
ing to the previously published protocol [17]. Briefly,
collagen gels were prepared by mixing 0.5 mL of fibro-
blast cell suspension (~2.5 × 105 cells) in FBS, 2.3 mL of
type I collagen (Cell matrix type IA; Nitta Gelatin,
Tokyo, Japan), 670 μL of 5× DMEM, and 330 μL of re-
constitution buffer, following the manufacturer’s rec-
ommendations. The mixture (3 mL) was cast into each
well of the six-well culture plates. The solution was
then allowed to polymerize at 37°C for 30 min. After
overnight incubation, each gel was detached and cultured
in growth medium, and the surface area of the gels was
quantified via densitometry (Densitograph, ATTO, Tokyo,
Japan) for 5 consecutive days, and the final size relative to
initial size was determined. For 3D co-culture, A549 cells
(2 × 105) were seeded on the surface of each gel prior to
overnight incubation. After 5 days of floating culture, the
gel was fixed in formalin solution and embedded in paraf-
fin, and vertical sections were stained with hematoxylin
and eosin.
Statistics
Results were confirmed by performing experiments in
triplicate. Analyses were performed using JMP version
9 (SAS Institute Inc., Tokyo, Japan). For statistical sig-
nificance, differences between two experimental groups
were examined using Student’s t-test, and Dunnett’s test
was used for multiple comparisons with control group.
P < 0.05 was considered to indicate significance.
GSEA (gene set enrichment analysis)
Navab et al. reported gene expression profiles for 15 pairs
of lung CAFs and NFs, and identified genes enriched in
lung CAFs [21]. GSEA was performed using these micro-
array data sets (GSE22862) deposited in the public data-
base. To obtain a gene set regulated by TGF-β, we used
publicly available microarray datasets, derived from two
lung fibroblast cell lines stimulated by TGF-β: HFL-1
(GSE27597) and IMR-90 (GSE17518) [22,23]. We ex-
tracted the top 800 TGF-β-induced genes from each
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of Microarrays (SAM) method. Combining these two
gene lists, we isolated 196 commonly induced genes in
two lung fibroblast cell lines, which were defined as
‘TGF-β-regulated genes’ (Additional file 3: Table S3).
Results
TGF-β signaling is activated in lung CAFs
CAFs are a major constituent of the tumor stroma, and
we have previously shown that lung CAFs are more potent
in enhancing cancer cell invasion and collagen gel con-
traction than normal lung fibroblasts (NFs) [17]. Although
the role of TGF-β in cancer cells and lung fibroblasts has
been investigated extensively, TGF-β function in CAFs
remains largely unknown due to technical hurdles in
isolating fibroblasts from lung cancer tissues.
To examine TGF-β signaling activation status in lung
CAFs, we used gene set enrichment analysis (GSEA) to
determine whether the expression of the identified TGF-
β-regulated genes was enhanced in lung CAFs compared
to NFs. This was performed using microarray data sets
of CAFs and NFs reported by Navab et al. [21]. These
analyses demonstrated that the TGF-β-regulated genes
identified through our analysis are in fact highlyFigure 1 Gene set enrichment analysis (GSEA). A: GSEA was used to ex
‘TGF-β-regulated genes’ include 196 genes induced by TGF-β in both IMR-9
profiles reported by Navab et al. [21] were used. Enrichment of TGF-β-regu
the CAF phenotype on the left (‘CAF-high’) and the genes that best correla
representing the relative expression change of ‘ 88 leading edge genes’ wh
representing the relative expression change of selected ‘16 ECM related geenriched in CAFs, suggesting that TGF-β signaling is ac-
tivated in lung CAFs (Figure 1A). We further extracted
88 ‘leading edge genes’ out of the TGF-β-regulated
genes. A heatmap of these leading edge genes clearly
illustrated differential expression between CAFs and
NFs (Figure 1B). As expected, ECM-related genes were
enriched among the leading edge genes, and a heatmap of
16 selected ECM related genes apparently showed that
TGF-β-regulated ECM-related enzymes and substrates,
including PLOD1, LOX, COL1A1, VCAN, SPARC, FN1,
ELN, and THBS1, are more enriched in CAFs than NFs
(Figure 1C).
Lentivirus-mediated transduction of artificial miRNAs
against human TGF-β1 and TGF-β2
Based on the observation that endogenous TGF-β signal-
ing is activated in lung CAFs, we examined whether TGF-
β signaling activation in fibroblasts modulates the behavior
of adjacent cancer cells. We also aimed to elucidate the
cell-autonomous action of TGF-β in lung cancer cells. To
this end, we generated lentiviral vectors that transduced
artificial miRNAs against TGF-β ligands, and tested their
effects on lung cancer cells and HFL-1 lung fibroblasts.
The expression levels of TGF-β isoforms are variableamine the enrichment of identified TGF-β-regulated genes in CAFs.
0 and HFL-1 lung fibroblast cell lines. CAF and NF gene expression
lated genes is shown schematically with those that best correlated with
ted with the NF phenotype on the right (‘NF-high’). B: A heat map
ich were obtained by GSEA analysis in CAFs and NFs. C: A heat map
nes’.
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ferences, we used Cancer Cell Line Encyclopedia (CCLE)
data and found that expression of TGF-β isoforms are
relatively high in A549 cells among 111 non-small cell
lung cancer cell lines (Additional file 4: Figure S1). There-
fore, we used A549 lung cancer cells in the following
experiments.
Four miRNA sequences were designed to target hu-
man TGF-β1, as well as three sequences against TGF-β2
(Additional file 1: Table S1). Next, we determined the ef-
ficiency of lentiviral infection by measuring the percent-
age of EmGFP-positive cells using flow cytometry. More
than 95% of A549 cells were positive for EmGFP, sug-
gesting a high transduction efficiency for this miRNA
sequence (Additional file 5: Figure S2A, left); we ob-
served similar efficiencies for all miRNA sequences used
in this study (Additional file 5: Figure S2A, right).
Meanwhile, HFL-1 cells showed more modest (but still
sufficient) efficiencies for lentiviral infection (Additional
file 5: Figure S2B, left). The percentage of EmGFP-
positive cells ranged from 65–85% among the miRNA
sequences (Additional file 5: Figure S2B, right).
For double knockdown of TGF-β1 and TGF-β2, two
combinations of lentiviruses encoding miRNAs against
TGF-β1 and TGF-β2 were co-infected: #2 miRNA against
TGF-β1 and #2 miRNA against TGF-β2 (TGF-β1KD #2+
TGF-β2KD #2), or #4 miRNA against TGF-β1 and #3
miRNA against TGF-β2 (TGF-β1KD #4+ TGF-β2KD #3).
Co-infection with two different lentiviruses showed similar
transduction efficiencies compared to single infections, as
determined via EmGFP fluorescence (Additional file 5:
Figure S2A, right and Additional file 5: Figure S2B, right).
Potent and selective knockdown of TGF-β1 and TGF-β2
Next, we evaluated the efficiency of TGF-β knockdown
through measurement of protein expression via ELISA.
To control for unintended effects of experimental ma-
nipulation, we examined the expression of TGF-β1 and
TGF-β2 in uninfected A549 and HFL-1 cells compared
to cells infected with negative control (NTC) miRNAs
(Figure 2). No significant difference in TGF-β1 or TGF-β2
expression was observed.
In A549 cells, three of four miRNAs against TGF-β1
(#1, #2, and #4) were able to silence TGF-β1 expression,
whereas all three miRNAs against TGF-β2 were ineffective
for TGF-β1 (Figure 2A, left). Two out of three miRNAs
against TGF-β2 (#2 and #3) silenced TGF-β2 expression,
whereas all four miRNAs against TGF-β1 were ineffective
for TGF-β2 (Figure 2A, right). In HFL-1 cells, three of
four miRNAs against TGF-β1 (#1, #2 and #3) were able to
silence TGF-β1 expression, whereas all three miRNAs
against TGF-β2 were ineffective for TGF-β1 (Figure 2B,
left). Two of three miRNAs against TGF-β2 (#2 and #3) si-
lenced TGF-β2 expression, whereas all four miRNAsagainst TGF-β1 were ineffective for TGF-β2 (Figure 2B,
right). These results show that miRNAs against TGF-β1
or TGF-β2 exert their effects in a selective manner for
each ligand. Out of the two combinations tested for
double knockdown, miRNA #2 against TGF-β1 and #2
against TGF-β2 showed efficient silencing in both A549
and HFL-1 cells (Figure 2). Therefore, we selected miRNA
sequences #2 against TGF-β1 and #2 against TGF-β2, for
single or double knockdown in the following experiments.Cell proliferation is suppressed by knockdown of TGF-β1
and/or TGF-β2
Next, we investigated whether TGF-β1 and/or TGF-β2
knockdown affected the proliferation of A549 and HFL-1
cells. In both cell types, the transduction of artificial
miRNAs against TGF-β1 or TGF-β2 suppressed cell
proliferation (Figure 3), and this anti-proliferative effect
was enhanced in cells subject to double knockdown, com-
pared to single knockdown of either TGF-β1 or TGF-β2.
TGF-β is a strong inhibitor of proliferation in most
epithelial cells, whereas it promotes proliferation in mes-
enchymal cells and enhances cancer cell survival [6-8].
Our lentivirus-mediated miRNA delivery system main-
tains stable knockdown of TGF-β1 and/or TGF-β2. This
may alter cell signaling in the steady state and modulate
the cell machinery that regulates cell survival or prolifer-
ation, thereby resulting in suppressed cell proliferation.Altered EMT-related gene expression via TGF-β1 and/or
TGF-β2 knockdown
EMT is crucial for cancer cells to acquire invasive pheno-
types, which are characterized by downregulation of E-
cadherin and upregulation of vimentin. A549 cells stay in
an intermediary state of EMT, whereas exogenous TGF-β
further promotes acquisition of mesenchymal phenotypes
[20]. We examined whether knockdown of TGF-β ligands
modulated the expression of EMT markers.
Silencing of TGF-β2 led to E-cadherin upregulation,
suggesting the restoration of epithelial phenotypes. In ac-
cordance, vimentin expression was suppressed by knock-
down of TGF-β1 and/or TGF-β2, though it failed to reach
statistical significance (Figure 4A). These results support
the notion that endogenous TGF-β signaling participates
in the maintenance of a mesenchymal phenotype in A549
cells in the steady state.
EMT is accompanied by the enhanced expression
of fibrogenic growth factors, such as platelet-derived
growth factor (PDGF) and connective tissue growth fac-
tor (CTGF) [20]. PDGF is a dimeric protein composed
of A and B subunits, and it has been reported that the
transcription of PDGFB is regulated by TGF-β. Consist-
ent with the previous experiment [20], TGF-β2 silencing
led to CTGF downregulation, whereas knockdown of
Figure 2 Knockdown of TGF-β ligands. A: TGF-β1 and TGF-β2 concentrations measured by ELISA in the supernatant of A549 cells transduced
with each miRNA. Left: TGF-β1. Right: TGF-β2. Data shown are the means ± SEM of triplicate analyses. KD: knockdown. NTC: negative control. The
concentration of TGF-β1 or TGF-β2 in the supernatant of cells with TGF-β1 and/or TGF-β2 knockdown was compared to that of cells transduced
with NTC miRNA. Statistical significance was determined by Dunnett’s test. *P < 0.05. B: TGF-β1 and TGF-β2 concentrations measured by ELISA in
the supernatant of HFL-1 cells.
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(Figure 4B).
Upon TGF-β stimulation, fibroblasts convert to an acti-
vated phenotype to enhance ECM production. Thus, we
examined whether knockdown of TGF-β1 and/or TGF-β2
modulated the expression of α1 (I) collagen (COL1A1), a
major component of ECM. In HFL-1 cells, TGF-β1 knock-
down decreased the expression of COL1A1, whereas
TGF-β2 silencing had no effect (Figure 4C).
These results suggest the differential regulation of
target genes by TGF-β1 or TGF-β2 in cancer cells and
fibroblasts. During lung branching morphogenesis,
TGF-β1 expression is prominent throughout the mes-
enchyme, whereas TGF-β2 is localized to mainly the
epithelium of the developing distal airways [24]. Thus,
TGF-β2 may be critical for determining epithelial or
cancer cell behavior in a cell-autonomous fashion,
whereas endogenous TGF-β1 may play a greater role in
fibroblasts.TGF-β1 and/or TGF-β2 knockdown attenuates collagen
gel contraction in HFL-1 cells
Cancer tissue contraction facilitates tumor progression
and contributes to increased interstitial fluid pressure,
which hampers drug delivery [5]. The collagen gel con-
traction assay is used widely to recreate tissue contraction
in an experimental setting, and it has been shown that
TGF-β stimulates fibroblast-mediated collagen gel con-
traction [25]. We used this assay to investigate whether
knockdown of TGF-β1 and/or TGF-β2 modulated tissue
contraction through effects on fibroblasts.
Collagen gels were embedded with HFL-1 cells after
TGF-β1 and/or TGF-β2 knockdown, and gel size was
measured daily. On the first day, the control gel size was
reduced to ~50% of the initial value, followed by gradual
shrinkage to less than 20% on the fifth day (Figure 5).
Compared to the control, knockdown of TGF-β1 and/or
TGF-β2 in HFL-1 cells attenuated gel contraction (Figure 5
and Additional file 6: Figure S3). These results suggested
Figure 3 Cell proliferation assay. Cell proliferation curve in A549 or HFL-1 cells transduced with NTC miRNA (solid line) compared to cells transduced
with miRNA against TGF-β1 (dashed line: TGF-β1 KD), TGF-β2 (dotted line: TGF-β2 KD), or TGF-β1 and TGF-β2 (dashed-dotted line: TGF-β1 + β2 KD). Cell
counts were carried out on days 1, 3, and 5 after seeding. Left: A549. Right: HFL-1. Data shown are the means ± SEM of triplicate analyses. Numbers of cells
with TGF-β1 and/or TGF-β2 knockdown on day 5 was compared to that in the cells transduced with NTC miRNA. Statistical significance was determined
by Student’s t-test. *P < 0.05.
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fibroblasts ameliorates tissue contraction.Three-dimensional co-culture of A549 and HFL-1 cells
To examine the interaction between lung cancer cells
and fibroblasts, we previously established a 3D co-culture
model [17]. HFL-1 cells transduced with control miRNAs
or those for TGF-β1 and TGF-β2 silencing (double knock-
down) were embedded into the collagen gels, and then
A549 cells were seeded onto the surface of these gels. The
co-cultured collagen gels were subjected to floating cul-
ture for an additional 5 days, followed by hematoxylin and
eosin staining (Figure 6).
Double knockdown of TGF-β1 and TGF-β2 in HFL-1
cells did not show clear effects on A549 cell invasion,
suggesting a minor role for TGF-β produced in HFL-1
cells in this co-culture model (lower panels). In our
previous work, we did not examine whether HFL-1
cells enhance lung cancer cell invasion [17], and this
study suggests that endogenous TGF-β expression in
HFL-1 cells may not have a significant role in invasion
promotion.
In contrast, A549 cell invasion was observed when
control A549 cells were cultured with control HFL-1
cells (upper left panel). Silencing of either TGF-β1 or
TGF-β2 in A549 cells failed to inhibit invasion (upper
middle panels), whereas double knockdown of TGF-β1
and TGF-β2 led to complete disappearance of invading
cells (upper right panel).Discussion
TGF-β plays several crucial roles in cancer progression,
affecting both tumor and stromal cells, including fi-
broblasts [4]. However, very little is known regarding
the effects of TGF-β ligand silencing in the context
of tumor–stromal or epithelial–mesenchymal interac-
tions [26]. Numerous reports have shown the effects
of exogenous TGF-β stimulation in various cell types,
whereas the effects of endogenous or cell-autonomous
TGF-β signaling are poorly understood. To our know-
ledge, this study is the first to generate lentiviral vectors
encoding artificial miRNAs targeting human TGF-β1 and
TGF-β2, and to explore their effects in a co-culture
model.
Lentiviral vectors showed efficient transduction in A549
lung cancer cells, as well as HFL-1 lung fibroblasts.
Knockdown efficiency to less than 30% of the control was
obtained for both TGF-β1 and TGF-β2 in a selective
manner. Knockdown of TGF-β ligands suppressed cell
proliferation in both A549 and HFL-1 cells. Furthermore,
expression of EMT markers and fibrogenic growth factors
was modulated in A549 cells, whereas collagen I was
downregulated in HFL-1 cells. With regard to cellular
function, silencing of TGF-β ligands attenuated HFL-1-
mediated collagen gel contraction, and inhibited A549 cell
invasion in the 3D co-culture model. All of these findings
support the tumor-promoting role of TGF-β, and that
the reported beneficial effects of TGF-β inhibition in
cancer therapeutics may derive from interfering with
tumor–stromal communications.
Figure 4 Quantitative RT-PCR. A: Quantitative RT-PCR for E-cadherin (left) and vimentin (right) in A549 cells. B: Quantitative RT-PCR for CTGF
(left) and PDGFB (right) in A549 cells. C: Quantitative RT-PCR for COL1A1 in HFL-1 cells. Data shown are the means ± SEM. The relative expression
of each gene in cells with TGF-β1 and/or TGF-β2 knockdown was compared to that in the cells transduced with NTC miRNA. Statistical significance
was determined by Student’s t-test. *P < 0.05.
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TGF-β2 were abundantly produced in A549 cells, whereas
the concentration of TGF-β1 was higher than that of
TGF-β2 in the supernatant of HFL-1 cells. Compared to
single knockdown, double knockdown of TGF-β1 and
TGF-β2 showed stronger effects in A549 cell proliferationand invasion in a 3D co-culture. In HFL-1 cells, TGF-β1
knockdown was more effective than TGF-β2 knockdown
in suppressing COL1A1 expression.
Little is known regarding the expression profiles of
TGF-β isoforms in various lung cancer cell types. As
























TGF- 1+ 2 KD
***
Figure 5 Collagen gel contraction assay. Time-course of gel
contraction in the presence of HFL-1 transduced with NTC miRNA
(solid line), or miRNAs against TGF-β1 (dashed line: TGF-β1 KD), TGF-β2
(dotted line: TGF-β2 KD), or TGF-β1 and TGF-β2 (dashed-dotted line:
TGF-β1 + β2 KD). The area of each gel was assessed daily for 5 days
and the relative value compared to the initial size was determined.
Data shown are the means ± SD of triplicate analyses. Statistical
significance was determined by Student’s t-test. *P < 0.05.
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These effects may be much more complicated and variable
depending on the multicellular context; nevertheless, our
results demonstrate the important role for TGF-β signal-
ing in the tumor microenvironment.
We have reported previously that lung CAFs enhance
cancer cell invasion [17]. In the present study, doubleFigure 6 3D co-culture model. Hematoxylin and eosin staining of 3D cul
indicated miRNAs. Upper panels: HFL-1 cells transduced with NTC miRNA. L
TGF-β2 (TGF-β1 + β2 KD). Invading cells are indicated with arrows. Scale baknockdown of TGF-β1 and TGF-β2 in HFL-1 cells did
not show clear effects on A549 cell invasion, and en-
dogenous TGF-β expression in HFL-1 cells seemed to
have little effect on lung cancer cell invasion. The pre-
cise mechanism underlying CAF-enhanced lung cancer
cell invasion remains to be elucidated, and further stud-
ies are necessary to clarify the mechanisms underlying
cell invasion in our experimental model.
There have been several attempts to exploit TGF-β
signaling inhibition as a therapeutic approach for malig-
nant tumors, including the use of TGF-β receptor kinase
inhibitors, TGF-β neutralizing antibodies, TGF-β anti-
sense oligonucleotides (AONs), and siRNAs [27]. TGF-β
type I receptor kinase inhibitor has been tested for non-
small cell lung cancer (NSCLC) patients in a phase II
study, but failed to yield clinical benefits [28]. Several
animal models of cancer have demonstrated the thera-
peutic effect of TGF-β neutralizing antibodies [29].
Recently, AONs against TGF-β ligands have shown
promising clinical results. Trabedersen (AP 12009) is an
AON against human TGF-β2. Intra-tumoral administra-
tion of trabedersen in patients with high-grade gliomas
led to better tumor control and prolonged survival with
fewer adverse events, which prompted a larger phase III
trial [30]. Intravenous application of trabedersen in pa-
tients with other cancer types is also under evaluation. AP
11014, another AON targeting human TGF-β1, is cur-
rently in preclinical development for NSCLC treatment.
Furthermore, a phase II trial for belagenpumatucel-L, a
vaccine produced from NSCLC cells transfected with
TGF-β2 AON, has shown beneficial effects on survival
without any significant adverse effects; phase III studies in
lung cancer patients are ongoing [31]. RNAi targeting
TGF-β ligands is also emerging as a promising tool [13].
In animal experiments, RNAi agents against TGF-β1
demonstrated therapeutically beneficial effects, support-
ing progression toward future clinical applications [16].
This body of work demonstrates the intensifying interest
in TGF-β ligand silencing as a therapeutic approach fortured gels composed of A549 and HFL-1 cells transduced with the
ower panels: HFL-1 cells transduced with miRNAs against TGF-β1 and
r: 100 μm.
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http://www.biomedcentral.com/1471-2407/14/580lung cancer. To validate therapeutic strategies against
TGF-β ligands, it may be critical to target the appropriate
TGF-β isoform in a given cell type. The present study pro-
vides a useful experimental model to investigate the effect
of therapeutic agents targeting TGF-β ligands. Our results
suggest that targeting both TGF-β1 and TGF-β2 in lung
cancer cells is more effective than single knockdown. Fur-
thermore, TGF-β2 knockdown may play a more specific
role in lung cancer cells than in stromal cells, such as fi-
broblasts. Future studies are warranted to further elucidate
the therapeutical benefits of strategies against the different
TGF-β ligands.
Conclusion
Because TGF-β exerts it pleiotropic effects in a variety
of cells in the tumor microenvironment, it is useful to
evaluate the action of anti-TGF-β therapeutic agents in
multicellular culture conditions. Our 3D co-culture
model, demonstrated here, represents a useful tool for
evaluating differential effects on cancer cells and fibro-
blasts. In summary, we established a lentivirus-mediated
knockdown system for TGF-β ligands, which revealed
their multifaceted effects on cell proliferation, EMT, inva-
sion, and ECM remodeling.
Additional files
Additional file 1: Table S1. Sequences of artificial miRNAs against
TGF-β ligands.
Additional file 2: Table S2. Primers for RT-PCR.
Additional file 3: Table S3. The 196 ‘TGF-β-regulated genes’.
Additional file 4: Figure S1. Expression levels of TGF-β isoforms in
non-small cell lung cancer cell lines. The transcription levels of TGF-β1
and TGF-β2 in non-small cell lung cancer cell lines were retrieved from
Cancer Cell Line Encyclopedia (CCLE) database and shown in a scatter
plot. A549 cells showed relatively higher levels of TGF-β1 and TGF-β2.
Additional file 5: Figure S2. Transduction efficiency of lentiviral
vectors. A: Transduction efficiency of miRNAs in A549 cells. Left: miRNA
transduction was tracked by detecting EmGFP-positive cells using the
FL-1 channel of a flow cytometer. A representative result of #2 miRNA
transduction against TGF-β1 is shown. The grey and black peaks are from
uninfected and lentivirus-transduced cells, respectively. Right: transduction
efficiency of each miRNA. KD: knockdown. NTC: negative control. B:
Transduction efficiency of miRNA in HFL-1 cells.
Additional file 6: Figure S3. Collagen gel contraction assay.
Photographs of the gels on day 5 in the experiments shown in Figure 5.
Identically sized white circles in each well are shown to demonstrate the
differences in gel size.
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